What is the safest way to cross-taper from 10 milligrams of escitalopram (Lexapro) to duloxetine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Research

The safest way to cross taper from 10 mg of Lexapro to duloxetine is to do so gradually under medical supervision, starting with 10 mg of Lexapo and 30 mg of duloxetine for one week, then reducing Lexapro to 5 mg and increasing duloxetine to 60 mg for another week, and finally discontinuing Lexapro while maintaining duloxetine at 60 mg daily. This approach is supported by the most recent study 1, which highlights the importance of careful monitoring for serotonin syndrome when combining SSRIs with other medications, including SNRIs like duloxetine.

When cross-tapering, it's essential to monitor for side effects like:

  • Headaches
  • Dizziness
  • Nausea
  • Mood changes

The overlap period allows for a smoother neurotransmitter adjustment as both medications affect serotonin systems but through different mechanisms - Lexapro as a selective serotonin reuptake inhibitor (SSRI) and duloxetine as a serotonin-norepinephrine reuptake inhibitor (SNRI) 2, 3. Staying hydrated, maintaining regular sleep patterns, and avoiding alcohol during the transition can help reduce side effects.

It's also important to note that SSRIs, including Lexapro, can have adverse effects, such as an increased risk of suicidality in certain populations 2, and that duloxetine has its own set of potential side effects 4, 5. However, the gradual cross-tapering approach recommended here aims to minimize these risks while ensuring a smooth transition between medications.

References

Research

Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: analysis of The FDA Adverse Event Reporting System (FAERS).

Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2025

Research

Selective Serotonin Reuptake Inhibitors.

Handbook of experimental pharmacology, 2019

Research

Selective Inhibition of the Serotonin Transporter in the Treatment of Depression: Sertraline, Fluoxetine and Citalopram.

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.